Our research focuses on the immune response involved in neuroimmunology demyelinating diseases. We study disease pathogenesis of Multiple sclerosis (MS) and Neuromyelitis optica (NMO), using gene expression analysis and immunological methods, looking into a better understanding of disease pathogenesis and developing biomarkers to tailor better the therapy to the patients.

The main projects in our lab today:

Personalize medication:  While there are several potentially effective treatment options for MS and NMO, the choice of medication is made currently largely at random, resulting in high rate of failure and progression of disability. As for today, there are no reliable clinical or laboratory methods to predict response to treatment or disease progression and outcome. We are looking for biomarkers of disease prognosis and response to treatment in MS and NMO patients to promote personalize medication.

Myelin repair mechanisms: In MS, there is limited capacity for endogenous repair or remyelination, likely contributes to progressive disease. We study the mechanisms underlying myelin repair in different clinical manifestations of MS.